Euroopa Liit - eesti - EMA (European Medicines Agency)

ceva santé animale - nõrgestatud elusate marutaudivastaste vaktsiinide viirus, tüvi spbn gasgas - immunoloogilised ravimid jaoks canidae, live viral vaccines - red foxes (vulpes vulpes); raccoon dogs (nyctereutes procyonoides) - rebase ja marutaudi aktiivseks immuniseerimiseks marutaudi vastu, et ennetada nakatumist ja suremust.

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration limited - emicizumab - hemofiilia a. - antihemorraagilised ained - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra saab kasutada kõigis vanuserühmades.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pari pharma gmbh - tobramycin - respiratory tract infections; cystic fibrosis - antibacterials süsteemseks kasutamiseks, - vantobra on näidustatud krooniliste kopsu-nakkuse tõttu pseudomonas aeruginosa patsientidel vanuses 6 aastat ja vanemad koos tsüstiline fibroos (cf). tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ucb pharma s.a. - lakosamiid - epilepsiad, osaline - antiepileptics, - lacosamide ucb on näidustatud monotherapy ja adjunctive ravi ravi osaline algusega krambid koos või ilma sekundaarse teha üldistusi täiskasvanud, noorukid ja lapsed alates 4-aastastel epilepsia.

Euroopa Liit - eesti - EMA (European Medicines Agency)

nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - antibacterials süsteemseks kasutamiseks, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Euroopa Liit - eesti - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lümfoom, mantle-cell - antineoplastilised ained - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Euroopa Liit - eesti - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - sead - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mitu müeloomit - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

proveca pharma limited - enalapril (maleate) - südamepuudulikkus - reniini-angiotensiini süsteemi toimivad ained - treatment of heart failure.

Eesti - eesti - Ravimiamet

septodont - artikaiin+epinefriin (adrenaliin) - süstelahus kolbampullis - 40mg+0,005mg 1ml 1.7ml 400tk; 40mg+0,005mg 1ml 1.7ml 200tk; 40mg+0,005mg 1ml 1.7ml 50tk